Core Insights - The current market is experiencing volatility due to a government shutdown, impacting futures and investor sentiment [1] - The artificial intelligence boom is driving the tech-heavy Nasdaq towards all-time highs, with a focus on stock selection and profit-taking strategies [1] Group 1: Stock Analysis - The IBD Breakout Stocks Index highlights stocks like Charles Schwab (SCHW), Hims & Hers Health (HIMS), and CrowdStrike (CRWD) as key players to watch [2] - Emcor (EME) is noted for its AI infrastructure role, currently forming a second-stage flat base with a buy point of 667.64 [3] - CrowdStrike is targeting a buy point of 507.20 in a cup with handle formation, showing strong technical indicators [4] Group 2: Market Trends - AppLovin (APP) and Alphabet (GOOGL) are extended beyond their buy ranges, indicating strong market performance [5] - TE Connectivity (TEL) is recognized for its connections in AI infrastructure and is trading within buy range after clearing a buy point of 212.76 [7] - The IBD Breakout Opportunities ETF (BOUT) allows investors to gain exposure to the entire index, providing a diversified investment option [10]

Core Insights - Bristol Myers Squibb (BMS) has committed to using Veeva Vault CRM to enhance customer engagement and decision-making in healthcare [1][2][3] Company Developments - Veeva Systems announced the partnership with BMS, highlighting the integration of AI into the customer journey to improve healthcare practitioner engagement [2][3] - The first Veeva AI agents for Vault CRM, including Pre-call Agent, Content Agent, Free Text Agent, and Voice Agent, are expected to be available in December 2025 [3] Industry Impact - The collaboration aims to transform how healthcare practitioners access information about innovative medicines, thereby supporting BMS's mission to deliver life-changing treatments to patients [2][3] - Veeva Systems serves over 1,500 customers in the life sciences sector, indicating a strong market presence and commitment to innovation [4]

Core Viewpoint - Dividend cuts can present investment opportunities, as the negative news is often already priced in, leading to potential undervaluation of assets [3][7]. Group 1: Market Reactions to Dividend Cuts - Wall Street analysts and individual investors often react negatively to dividend cuts, leading to knee-jerk selling of affected funds [2][3]. - BlackRock Health Sciences Term Trust (BMEZ) experienced a dividend cut, prompting some investors to sell, but this creates opportunities for contrarian investors [3][5]. Group 2: Closed-End Funds (CEFs) Dynamics - CEFs operate differently from ETFs or mutual funds, raising a fixed pool of capital at launch, which can lead to inefficiencies in trading [4]. - When investors sell CEF shares without considering underlying assets, discounts can widen, creating buying opportunities for savvy investors [4][7]. Group 3: BMEZ Fund Characteristics - BMEZ currently yields 9.2% and trades at an 11% discount to its net asset value (NAV), indicating a potential buying opportunity [7][12]. - The fund's portfolio includes biotech and medical device companies that may benefit from a favorable regulatory environment [6][8]. Group 4: Key Holdings and Performance - Alnylam (ALNY), a top holding in BMEZ, focuses on innovative RNA interference therapies and has seen significant stock gains under previous administration policies [8][9]. - Veeva Systems (VEEV), another key holding, has also performed well historically, benefiting from a favorable mergers and acquisitions environment [9][10]. - Dexcom (DXCM), the third largest holding, produces continuous glucose monitors and has experienced substantial stock growth [11]. Group 5: Future Outlook - The current administration's policies may support the healthcare sector, particularly for companies in BMEZ's portfolio, which could lead to further growth [12].

Group 1 - Alnylam Pharmaceuticals Inc is focused on developing therapies based on RNA interference technology, which has shown promise in treating rare genetic diseases [1] - DexCom Inc specializes in continuous glucose monitoring systems for diabetes management, indicating a growing demand for innovative health technology solutions [1] - Veeva Systems Inc Class A provides cloud-based software solutions for the global life sciences industry, highlighting the increasing reliance on digital transformation in healthcare [1] Group 2 - BlackRock Health Sciences Trust II is an investment vehicle that targets companies in the health sciences sector, reflecting investor interest in healthcare as a resilient investment area [1]

Core Insights - TimesSquare Capital Management's "U.S. Focus Growth Strategy" reported strong performance in Q2 2025, with equities achieving double-digit returns as global economic activity expanded [1] - Growth indexes outperformed value counterparts, with U.S. small and mid-cap growth indexes showing better returns from stocks with high valuations, negative earnings, or low returns on equity [1] - The strategy returned 11.79% (gross) and 11.56% (net), compared to an 18.20% return for the Russell Midcap Growth Index [1] Company Focus: Veeva Systems Inc. (NYSE:VEEV) - Veeva Systems Inc. reported a one-month return of -0.14% and a 52-week gain of 24.85%, with a market capitalization of $45.009 billion as of September 10, 2025 [2] - The strategy received a 24% boost from Veeva Systems, which surpassed revenue and earnings expectations, achieving total revenue of $789 million [3][4] - Veeva's commercial subscription revenue growth accelerated, driven by its Crossix platform, and new AI-embedded features were announced for its Vault suite [3] Hedge Fund Interest - Veeva Systems was held by 61 hedge fund portfolios at the end of Q2 2025, an increase from 55 in the previous quarter [4] - Despite strong results, the company is not among the 30 most popular stocks among hedge funds, with some analysts suggesting other AI stocks may offer greater upside potential [4]

Core Insights - Gilead Sciences has committed to using Veeva Vault CRM, enhancing their long-standing partnership with Veeva Systems [1][2][7] - Veeva Vault CRM is designed to improve commercial execution through advanced AI capabilities, including pre-call planning and voice control [2][3] Company Overview - Veeva Systems provides cloud-based software and services tailored for the life sciences industry, serving over 1,500 customers, including major biopharmaceutical companies [3] - Gilead Sciences is a biopharmaceutical company focused on innovative medicines for life-threatening diseases, operating in over 35 countries [4]

Group 1 - Klarna Group priced its initial public offering (IPO) at $40 per share, raising $1.37 billion and achieving an initial valuation of $15.1 billion [1] - Klarna's IPO involved the sale of 34.3 million shares, exceeding the targeted range of $35-$37 [1] - Klarna positions itself as a digital bank rather than solely a "buy now, pay later" service, primarily operating in Europe, contrasting with Affirm Holdings, which focuses on the U.S. market [2] Group 2 - Affirm Holdings has seen its stock rally by 45% in 2025, indicating strong market performance [2] - Affirm Holdings received an upgrade in its IBD SmartSelect Composite Rating from 94 to 96, reflecting improved performance metrics [3][4]

Core Viewpoint - Veeva (NYSE: VEEV) is experiencing accelerated revenue growth, leading to a reiterated "buy" rating with a price target of $322 per share [1]. Company Overview - Veeva is positioned in the market as a growth-driven company focusing on sustainable investment strategies [1]. Investment Strategy - The investment strategy emphasizes maximizing shareholder equity by targeting companies that meet growth-oriented goals [1]. Analyst Background - The analyst has extensive experience in high-growth supply-chain start-ups and has worked with venture capital firms, enhancing user acquisition and maximizing returns during the pandemic [1]. Financial Literacy - The analyst aims to democratize financial literacy, making complex macroeconomic concepts more accessible and empowering for investors [1].

Financial Data and Key Metrics Changes - Revenue for Q2 2026 was $10,250,000,000, representing a 10% increase year over year and a 9% increase in constant currency [7][44] - Non-GAAP operating margin was strong at 34.3%, with CRPO at $29,400,000,000, up 11% year over year [7][45] - Operating cash flow is expected to reach nearly $15,000,000,000, with a guidance increase for fiscal year 2026 revenue to $41,100,000,000 to $41,300,000, reflecting growth of approximately 8.5% to 9% year over year [7][53] Business Line Data and Key Metrics Changes - AI and data product line saw a remarkable 120% year-over-year growth [7] - Net new bookings from deals over $1,000,000 grew 26% year over year, indicating strong sales momentum [7] - Subscription and support revenue grew slightly above 9% in constant currency, driven by strong execution [44][45] Market Data and Key Metrics Changes - Strong new business growth was observed in the U.S. and pockets of EMEA, particularly in The Netherlands and Switzerland, while The UK and Japan faced constraints [46] - Technology and communications sectors performed well, while retail, consumer goods, and public sector remained measured [46] Company Strategy and Development Direction - The company is focusing on the concept of the "agentic enterprise," which emphasizes the integration of AI and human collaboration to transform business operations [8][12] - Strategic priorities include delivering customer success, accelerating data and AI adoption, and maintaining a responsible capital allocation strategy [47][51] - The company is expanding its offerings in the public sector and launching a new IT service platform, AgenTeq, to enhance operational efficiency [28][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the transformative potential of AI and the agentic enterprise, stating that this is a pivotal moment in the industry [10][37] - The company anticipates a record year and is raising guidance based on strong performance and customer demand [7][53] - Management highlighted the importance of Data Cloud as a strategic asset for future growth, with significant customer adoption [25][24] Other Important Information - The company returned $2,600,000,000 to shareholders through buybacks and dividends in Q2, with a total of nearly $27,000,000,000 returned since the program began [52] - The company is actively pursuing acquisitions to enhance its capabilities, including recent deals with Convergence.ai and Bluebirds [51] Q&A Session Summary Question: How defensible is SaaS against disruption from AI-native apps? - Management acknowledged the transformation in the software industry driven by AI, emphasizing that Salesforce has been integrating AI for over a decade and is well-positioned to extend its SaaS offerings [60][66] Question: What caused the 60% increase in pilot to production conversions? - Management indicated that close collaboration with customers and enhancements in product features have facilitated faster transitions from pilot to production [74][76] Question: What does a production deal look like around AgentForce? - Management highlighted that successful production deals involve leveraging Data Cloud and integrating various systems to enhance customer interactions and operational efficiency [82][85]

Core Insights - Veeva Systems has announced a collaboration with Amgen to enhance clinical trial innovation, utilizing the Veeva Clinical Platform to improve efficiencies in the clinical trial process [1][2][3] Group 1: Collaboration Details - Amgen aims to leverage advanced technology through this collaboration to enhance its end-to-end trial operations, which is expected to expedite the delivery of innovative treatments to patients [2] - The Veeva Clinical Platform will serve as the backbone for standardized and connected processes, facilitating faster delivery of life-saving drugs [3] Group 2: Veeva Clinical Platform Overview - The Veeva Clinical Platform is a comprehensive and connected solution that encompasses various clinical operations and data applications, including CTMS, EDC, clinical workbench, RTSM, eCOA, eTMF, and more [4] - This platform is designed to streamline clinical trials from initiation to completion, automating data flow and enhancing operational efficiency [4] Group 3: Company Background - Veeva Systems provides industry-specific cloud solutions for life sciences, serving over 1,500 customers, including major biopharmaceutical companies and emerging biotech firms [5] - The company is committed to innovation, product excellence, and balancing the interests of all stakeholders, including customers, employees, and shareholders [5]